Comparison
Cagrilintide vs. GHK-Cu
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Cosmetic
CAS no.
1415456-99-3
49557-75-7
Molecular weight
4253.7 g/mol
340.4 g/mol
Half-life
168 h
no data
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYGHKMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
GHK-Cu
Endogenous tripeptide (glycyl-L-histidyl-L-lysine) that chelates copper(II) ions. In skin-cell models and skin biopsies an influence on collagen synthesis, antioxidant markers, gene-expression profiles and wound-healing processes has been described. In topical use in cosmetic studies, changes in various skin parameters have been reported.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
3
of which in humans
3
1
Effects recorded
3
4
Open conflicts
0
1
Documented adverse events
1
2